Targeting FOXA1 and FOXA2 disrupts the lineage-specific oncogenic output program in prostate cancer

Activation of the androgen receptor (AR) is the key lineage-specific oncogenic pathway and the primary therapeutic target in prostate cancer. While AR signaling is enabled by the pioneer transcription factor FOXA1, its homolog FOXA2 is specifically expressed in advanced lineage-plastic prostate cancers that have lost the AR signaling axis. However, their roles and utility as drug targets remain incompletely characterized. Here, we show an unexpected collaboration of FOXA1 and FOXA2 in mediating AR-independent cell proliferation in different lineage-plastic cancer subtypes. Conversely, joint loss-of-function or pharmacologic disruption of FOXA1 and FOXA2 leads to the collapse of lineage-specific oncogenic transcription factors followed by cell-cycle arrest. In summary, our findings uncover a druggable dependency for AR-positive and -negative prostate cancers.

Authors

Institutions

Publication Details

Journal
Cell Reports
Published
2025-09-27
DOI
https://doi.org/10.1016/j.celrep.2025.116324
Citations
2
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
3.04
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Targeting FOXA1 and FOXA2 disrupts the lineage-specific oncogenic output program in prostate cancer

Federico Costanzo, Jean‐Philippe Theurillat, Matteo Pecoraro, Giada Andrea Cassanmagnago et al.
2 citations
Cell Reports
Prostate Cancer Treatment and Research
3.04
article

Targeting FOXA1 and FOXA2 disrupts the lineage-specific oncogenic output program in prostate cancer

Federico Costanzo, Jean‐Philippe Theurillat, Matteo Pecoraro, Giada Andrea Cassanmagnago, Daniela Bossi, Marco Coazzoli, Roger Geiger, Andrea Rinaldi, Marco Bolis, Diego Camuzi Cassiano, Claudio Lorenzi, Jacopo Sgrignani, Gayathri Thillaiyampalam, Raffaella Santoro, Nicolò Formaggio, Andrea Cavalli, Yanick Uebelhart
article en
2 citations

Abstract

Activation of the androgen receptor (AR) is the key lineage-specific oncogenic pathway and the primary therapeutic target in prostate cancer. While AR signaling is enabled by the pioneer transcription factor FOXA1, its homolog FOXA2 is specifically expressed in advanced lineage-plastic prostate cancers that have lost the AR signaling axis. However, their roles and utility as drug targets remain incompletely characterized. Here, we show an unexpected collaboration of FOXA1 and FOXA2 in mediating AR-independent cell proliferation in different lineage-plastic cancer subtypes. Conversely, joint loss-of-function or pharmacologic disruption of FOXA1 and FOXA2 leads to the collapse of lineage-specific oncogenic transcription factors followed by cell-cycle arrest. In summary, our findings uncover a druggable dependency for AR-positive and -negative prostate cancers.

Cell ReportsVol. 44(10)
University of Zurich (CH)
Openalex Percentile: Top 8%
Prostate Cancer Treatment and Research
3.04
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.